Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

Abpro is taking a second run at the public markets. Five years after pulling out of a planned IPO, the antibody specialist is back with a special purpose acquisition company, agreeing to combine with Atlantic Coastal Acquisition Corp. II to secure a Nasdaq listing and cash for a pipeline dominated by preclinical immuno-oncology programs.